ReShape Lifesciences Files S-1/A Amendment

TL;DR

ReShape Lifesciences (RSLS) filed an S-1/A, updating its registration. Keep an eye on this.

AI Summary

ReShape Lifesciences Inc. filed an S-1/A amendment on January 15, 2025, for its registration statement (No. 333-283952). The company, formerly Obalon Therapeutics Inc. until February 20, 2008, is incorporated in Delaware and operates in the Pharmaceutical Preparations sector. Its principal executive offices are located at 18 Technology Dr, Suite 110, Irvine, California 92618.

Why It Matters

This filing indicates ongoing regulatory processes for ReShape Lifesciences, potentially related to stock offerings or other securities transactions, which could impact investors and the company's financial structure.

Risk Assessment

Risk Level: medium — S-1/A filings often relate to capital raises or significant corporate actions, which carry inherent financial and market risks for investors.

Key Numbers

• 333-283952 — Registration Statement Number (Identifies the specific SEC filing for ReShape Lifesciences Inc.)

Key Players & Entities

• ReShape Lifesciences Inc. (company) — Registrant
• 333-283952 (dollar_amount) — Registration Statement Number
• January 15, 2025 (date) — Filing Date
• Obalon Therapeutics Inc. (company) — Former Company Name
• February 20, 2008 (date) — Date of Name Change
• 18 Technology Dr, Suite 110, Irvine, California 92618 (location) — Principal Executive Offices
• Paul F. Hickey (person) — President and Chief Executive Officer

FAQ

Key Financial Figures

• $833.333 — ote in the original principal amount of $833.333.34 that we issued to Ascent on October
• $5.22 — 2024 at an initial conversion price of $5.22 per share (the "Convertible Note") and
• $5,000,000 — we may receive gross proceeds of up to $5,000,000 from the sale of common stock to Ascent
• $1.15 million — development has received approximately $1.15 million dollars of nondilutive NIH grant suppor
• $5.16 million — ur liabilities, for a purchase price of $5.16 million in cash, subject to adjustment based on

Filing Documents

• tm2431533-3_s1a.htm (S-1/A) — 3621KB
• tm2431533d5_ex23-2.htm (EX-23.2) — 2KB
• tm2431533d5_ex23-3.htm (EX-23.3) — 2KB
• lg_reshapelifescitm-4clr.jpg (GRAPHIC) — 14KB
• fc_keygrowth-4clr.jpg (GRAPHIC) — 74KB
• 0001104659-25-003522.txt ( ) — 3749KB

RISK FACTORS

RISK FACTORS 11 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 49 CAPITALIZATION 50

USE OF PROCEEDS

USE OF PROCEEDS 51 MARKET AND DIVIDEND INFORMATION FOR OUR COMMON STOCK 52 DESCRIPTION OF EQUITY FINANCING TRANSACTION 53 DESCRIPTION OF CONVERTIBLE NOTE TRANSACTION 55 THE SELLING STOCKHOLDER 56

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 57 SECURITIES ACT RESTRICTIONS ON RESALE OF OUR SECURITIES 62 PLAN OF DISTRIBUTION 63 RESHAPE AND VYOME UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS 65 LEGAL MATTERS 77 EXPERTS 77 INCORPORATION OF CERTAIN INFORMATION BY REFERENCE 77 WHERE YOU CAN FIND MORE INFORMATION 78 DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITY 78 i TABLE OF CONTENTS ABOUT THIS PROSPECTUS This prospectus is part of a registration statement on Form S-1 under which the selling stockholder may, from time to time, sell the securities offered by them described in this prospectus. We will not receive any proceeds from the sale by the selling stockholder of the securities offered by them described in this prospectus. You should not assume that the information contained in this prospectus is accurate on any date subsequent to the date set forth on the front cover of this prospectus, even though this prospectus is delivered or our securities registered under the registration statement of which this prospectus forms a part are sold or otherwise disposed of on a later date. It is important for you to read and consider all information contained in this prospectus in making your investment decision. You should also read and consider the information in the documents to which we have referred you under the captions " Where You Can Find Additional Information " in this prospectus. Neither we nor the selling stockholder have authorized anyone to provide any information or to make any representation other than those contained in this prospectus. You must not rely upon any information or representation not contained in this prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This prospectus does not constitute an offer to sell or the solicitation of an offer to buy any of our securities other than the securities covered hereby, nor does

View Full Filing

View this S-1/A filing on SEC EDGAR